STAT3 and lung adenocarcinoma: Inhibition of STAT3 in human PC14PE6/AS2 lung adenocarcinoma cells reduces tumor-associated VEGF expression, angiogenesis, and vascular permeability [49], while pharmacologic inhibition or siRNA-mediated interference of JAK2/STAT3 signaling in A549 NSCLC cells impairs angiogenesis by decreasing VEGF expression [45,50].